European Heart Journal

Article	Citations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	5178
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)	4916
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation	2690
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice	2345
2021 ESC/EACTS Guidelines for the management of valvular heart disease	1974
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	949
2020 ESC Guidelines for the management of adult congenital heart disease	887
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy	817
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease	757
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death	676
COVID-19 is, in the end, an endothelial disease	656
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio	651
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era	646
Coronaviruses and the cardiovascular system: acute and long-term implications	507
Acute pulmonary embolism and COVID-19 pneumonia: a random association?	465
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe	432
Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage	432
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases	422
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy	403
Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin	400
An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcircula	369
Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection	368
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors	360
Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019	348
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study	341

European Society of Cardiology: cardiovascular disease statistics 2021	329
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis	322
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research	315
The ‘Digital Twin’ to enable the vision of precision cardiology	305
SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?	290
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery	284
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather	283
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study	282
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus	279
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement	274
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force	262
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance	259
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial	248
The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation	247
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine	242
2023 ESC Guidelines for the management of acute coronary syndromes	241
COVID-19-related myocarditis in a 21-year-old female patient	238
C-reactive protein and clinical outcomes in patients with COVID-19	233
Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts	224
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement	202
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study	193
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions	190
Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes	185
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyc	181
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study	179
COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests	177
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o	171
Targeting cardiovascular inflammation: next steps in clinical translation	165
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)	164
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy	164
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	160
Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19	160
Left bundle branch area pacing outcomes: the multicentre European MELOS study	155
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement	151
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials	150
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)	147
2023 ESC Guidelines for the management of cardiomyopathies	142
Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes	139
Prevalence of statin intolerance: a meta-analysis	137
Typical takotsubo syndrome triggered by SARS-CoV-2 infection	136
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction	136
The Mediterranean diet, plasma metabolome, and cardiovascular disease risk	135
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)	134
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial	132
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies	131
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study	131
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy	130
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists	129
The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020	125
Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation	124

Heart failure drug treatment: the fantastic four	123
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults	122
Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study	121
Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial	119
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF	116
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)	114
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes	114
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial	113
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials	113
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank	113
Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials	112
Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis	112
Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair	112
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial	112
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies	110
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank	110
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery	110
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction	109
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme	107
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial	106
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism	105
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial	103
Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study	101
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake	100
Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk	99
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study	99
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study	96
EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic	96
Vulnerable plaques and patients: state-of-the-art	94
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial	94
Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves	92
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up	92
Electrocardiogram screening for aortic valve stenosis using artificial intelligence	91
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry	91
Application of artificial intelligence to the electrocardiogram	91
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation	90
Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial	89
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS	89
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis	89
Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk	88
2023 ESC Guidelines for the management of endocarditis	88
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)	87
Combination lipid-lowering therapy as first-line strategy in very high-risk patients	87
Empagliflozin in acute myocardial infarction: the EMMY trial	87
Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype	86
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome	85
New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people	83
Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world	83
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a s	83
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial	82
Sex differences and temporal trends in aortic dissection: a population-based study of incidence, treatment strategies, and outcome in Swedish patients during 15 years	81
Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations	81
Genetic predisposition to smoking in relation to 14 cardiovascular diseases	80
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study	80
Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial	79
Colchicine and the heart	79
Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)	78
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial	78
Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy	78
Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group	78
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis	78
Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation	78
Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry	77
Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with th	77
Women who experience a myocardial infarction at a young age have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry	77
Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percuta	77
Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes	76
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials	75
The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EA	75
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk	75
Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction	75
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial	74
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy	74
Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study	74
Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study	74
Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial	74
The “ten commandments” for the 2021 ESC/EACTS Guidelines on valvular heart disease	73
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes	73
Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study	73
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial	72

Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease	72
Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies	72
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombo	71
Assessment and pathophysiology of microvascular disease: recent progress and clinical implications	71
Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance	70
The win ratio approach for composite endpoints: practical guidance based on previous experience	70
Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial	70
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials	70
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction	70
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial	70
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis	69
Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammatio	69
A practical risk score for early prediction of neurological outcome after out-of-hospital cardiac arrest: MIRACLE2	69
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis	69
Frailty and cardiovascular outcomes in the National Health and Aging Trends Study	69
Return to sports after COVID-19 infection	68
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy	68
CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure	67
Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study	67
The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction	67
Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the E	67
Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction	66
Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translat	66
Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy	66
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial	66
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis	65
Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study	65
Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality	65
Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study	65
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study	64
Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak	64
Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)	64
Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up	63
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the He	63
Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole	63
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study	63
Feasibility of using deep learning to detect coronary artery disease based on facial photo	63
Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models	63
Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data	62
Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial	62
Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention	62
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme	62
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis	62
Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences	61
Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection	61
Twitter promotion predicts citation rates of cardiovascular articles: a preliminary analysis from the ESC Journals Randomized Study	61
COVID-19: from epidemiology to treatment	61
STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases	60
The ‘10 commandments’ for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy	60
Assessing left ventricular systolic function: from ejection fraction to strain analysis	60
Transient complete heart block in a patient with critical COVID-19	60
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality	60
Targeting the CCL2–CCR2 axis for atheroprotection	59
The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms	59
Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associated myocardial involvement	59
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology	58
Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19	58
Road traffic noise and cardiovascular disease risk factors in UK Biobank	58
Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial	58
Genetic variability in the absorption of dietary sterols affects the risk of coronary artery disease	57
Health system, public health, and economic implications of managing COVID-19 from a cardiovascular perspective	57
Brugada syndrome genetics is associated with phenotype severity	57
Outdoor light at night and risk of coronary heart disease among older adults: a prospective cohort study	57
Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data	57
TeleCheck-AF for COVID-19	57
Metoprolol exerts a non-class effect against ischaemia–reperfusion injury by abrogating exacerbated inflammation	57
Effects of canagliflozin on human myocardial redox signalling: clinical implications	57
Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study	57
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases	57
A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study	56
Acute mental stress drives vascular inflammation and promotes plaque destabilization in mouse atherosclerosis	56
Does epicardial fat contribute to COVID-19 myocardial inflammation?	55
A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs	55
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial	55
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey	55
Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis	55
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score	55
Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank	54
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial	54
The struggle towards a Universal Definition of Heart Failure—how to proceed?	54
Sex differences in arterial hypertension	54
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease	54
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR	54
Transition to adulthood and transfer to adult care of adolescents with congenital heart disease: a global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (A	53
Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry	53
Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial	53
Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death	53
Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial	53
Stress-associated neurobiological activity associates with the risk for and timing of subsequent Takotsubo syndrome	53
Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?	53
Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction	52
Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome	52
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary s	52
Adipocyte fatty acid-binding protein exacerbates cerebral ischaemia injury by disrupting the blood–brain barrier	52
The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy	51